Alteration of the Immune Microenvironment in Basal Cell Carcinoma Following Photodynamic Therapy
Alteration of the Immune Microenvironment in Basal Cell Carcinoma (BCC) Following Photodynamic Therapy (PDT)
Case Comprehensive Cancer Center
28 participants
Dec 13, 2021
INTERVENTIONAL
Conditions
Summary
The purpose of this study is to better understand the immune response to basal cell carcinoma (BCC) treated with Photodynamic Therapy (PDT) in order to develop new methods of treating BCC. Previous research suggests that PDT alters the immune response, possibly in a way that could promote better tumor clearance when combined with other treatments. Overall, participation in this study will help the study team better understand the anti-tumor immune response when BCC is treated with PDT.
Eligibility
Inclusion Criteria4
- Adults scheduled to undergo Mohs surgery within the Dermatologic Surgery unit of the Department of Dermatology, Cleveland Clinic
- Must have at least one BCC tumor eligible for removal by surgical excision
- Men and women of any ethnic group are eligible
- Must provide informed consent to participate
Exclusion Criteria4
- Pregnant or breastfeeding
- Currently being treated for other cancers with medical or radiation therapy
- Known hypersensitivity to 5-aminolevulinic acid (ALA)
- History of a photosensitivity disease, e.g.,porphyria cutanea tarda
Interventions
At first visit, ALA applied to one BCC lesion
PDT with blue light (for 30 min (\~20 mJ/cm2))
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05020912